SYNTHESIS AND CHARACTERIZATION OF A NEW METFORMIN - RESVERATROL ALDEHYDE LIGAND AND EVALUATION OF ITS GLUCOSE UPTAKE EFFICACY USING RAT L6 SKELETAL MUSCLE CELL LINES

Abstract

Diabetes is a chronic disorder that arises due to the deficiency (T1DM) and/or efficiency (T2DM) of insulin, a hormone secreted by the β cells of the pancreas. T2DM reports for about 90% of the total diabetic population. Among the various oral antidiabetic drugs having a different mechanism of action prescribed for the treatment of T2DM, metformin forms the backbone for individual and/or combination therapy. However, chronic administration of metformin at higher doses may induce lactic acidosis and vitamin B12 deficiency. To evade the toxicity of metformin at chronic doses, we have synthesized a new Metformin - Resveratrol Aldehyde (Met-RA) ligand. The molecular structure of the synthesized ligand was characterized by various spectral studies. To evaluate the antidiabetic properties of the synthesized ligand, the glucose uptake efficacy of the Met-RA ligand was determined using a differentiated rat skeletal muscle cell line. The efficacy of the ligand was compared with insulin, metformin, and resveratrol. The results obtained evidenced the significant glucose uptake properties of the metformin- resveratrol aldehyde ligand relatively at a lesser concentration than insulin